Vol. I · No. 1 · Taipei EditionThursday, 14 May 2026 · 2026-W20Last ingest 3d ago · 4/4 feeds

Agency Intel / TW

“Truth · Timing · Tradecraft” — the WPP Media Taiwan review-readiness desk
Dashboard · Roster · MNC Pharma · Sanofi Taiwan
№ 95 · The Sanofi Taiwan dossier

Sanofi Taiwan

賽諾菲台灣
Parent: Sanofi S.A. (Euronext Paris: SAN; NASDAQ: SNY)
Readiness
95
Greenfield
Capped at 95. High confidence — AOR sourced within 0y · high-confidence research.
Workspace · saved locally in your browser
Pipeline status
Your notes · Sanofi Taiwan
Saves on blur. Stored in your browser only — not synced.

Multi-business: Specialty Care (Dupixent, MS, rare disease), General Medicines, Vaccines (flu, pediatric, Nuvaxovid), Consumer Healthcare (Allegra — being spun out via Opella 2024-2025). WPP-dominant globally since 2017-2018: Mindshare for media (60+ countries), WPP creative agencies (GCI Health, VML) on corporate. TW: active Rx HCP, growing vaccine consumer awareness, OTC Allegra in transition.

Signal timeline · last 90 days
0 of 0 shown
No signals captured in the last 90 days. Account is monitored daily — next ingest will pick up MOPS filings + RSS hits automatically.
The arithmetic of 95
score breakdown
AOR 8y with Mindshare (WPP/GroupM) global media; WPP creative agencies GCI Health + VML on corporate brand; Publicis Health + Havas on selected creative scopesaor_anniversary_5y+55
Intel depth (6 wedges · recent)research_depth+45
Total · capped 9595
30-day signal trajectory
0 signals · spend N/A
Intel wedges
6/8
6 of 8 wedges corroborated. Research confidence: high — WPP/Mindshare 2017-2018 global media win publicly documented across AdWeek, Fierce Pharma, Campaign Asia, Mediapost. 'Miracles of Science' WPP creative credit (GCI Health + VML) publicly confirmed..
Open playbook →
Recommended posture
Pitch now.
WPP IS already the global Sanofi incumbent — this is a DEFEND + EXPAND pitch, not a displace pitch. Mindshare globally + WPP creative agencies on 'Miracles of Science' corporate brand.